Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma

Gynecologic Oncology

Volumn 114, Issue 3, 2009, Pages 390-394

  Quint, Koen D ^a   de Koning, Maurits N C ^a   Geraets, Daan T ^a   Quint, Wim G V ^a   Pirog, Edyta C ^b  

^a DDL DIAGNOSTIC LABORATORY   (Netherlands)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cervical adenocarcinoma; Chlamydia trachomatis; Endocervical adenocarcinoma; HPV

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA; ARTICLE; CARCINOGENESIS; CHLAMYDIA TRACHOMATIS; CONTROLLED STUDY; FEMALE; GENE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 40; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MIXED INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADENOCARCINOMA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DNA, VIRAL; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 67651152586     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.05.013     Document Type: Article

References (32)

1. Bray F., Carstensen B., Møller H., Zappa M., Zakelj M.P., Lawrence G., et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2191-2199
2. Vizcaino A.P., Moreno V., Bosch F.X., Muñoz N., Barros-Dios X.M., and Parkin D.M. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int. J. Cancer 75 (1998) 536-545
3. Liu S., Semenciw R., and Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ 164 (2001) 1151-1152
4. Kleter B., van Doorn L.J., ter Schegget J., Schrauwen L., van Krimpen K., Burger M., et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153 (1998) 1731-1739
5. Kleter B., van Doorn L.J., Schrauwen L., Molijn A., Sastrowijoto S., ter Schegget J., et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37 (1999) 2508-2517
6. Jacobs M.V., Snijders P.J., van den Brule A.J., Helmerhorst T.J., Meijer C.J., and Walboomers J.M. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35 (1997) 791-795
7. van den Brule A.J., Pol R., Fransen-Daalmeijer N., Schouls L.M., Meijer C.J., and Snijders P.J. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J. Clin. Microbiol. 40 (2002) 779-787
8. Pirog E.C., Kleter B., Olgac S., Bobkiewicz P., Lindeman J., Quint W.G., et al. Prevalence of human papillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am. J. Pathol. 157 (2000) 1055-1062
9. Anttila T., Saikku P., Koskela P., Bloigu A., Dillner J., Ikäheimo I., et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 285 (2001) 47-51
10. Smith J.S., Bosetti C., Muñoz N., Herrero R., Bosch F.X., Eluf-Neto J., et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int. J. Cancer 111 (2004) 431-439
11. Smith J.S., Muñoz N., Herrero R., Eluf-Neto J., Ngelangel C., Franceschi S., et al. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. J. Infect. Dis. 185 (2002) 324-331
12. Madeleine M.M., Anttila T., Schwartz S.M., Saikku P., Leinonen M., Carter J.J., et al. Risk of cervical cancer associated with Chlamydia trachomatis antibodies by histology, HPV type and HPV cofactors. Int. J. Cancer. 120 (2007) 650-655
13. Wallin K.L., Wiklund F., Luostarinen T., Angström T., Anttila T., Bergman F., et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int. J. Cancer 101 (2002) 371-374
14. Samoff E., Koumans E.H., Markowitz L.E., Sternberg M., Sawyer M.K., Swan D., et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am. J. Epidemiol. 162 (2005) 668-675
15. Silins I., Ryd W., Strand A., Wadell G., Törnberg S., Hansson B.G., et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer. 116 (2005) 110-115
16. Paba P., Bonifacio D., Di Bonito L., Ombres D., Favalli C., Syrjänen K., et al. Co-expression of HSV2 and Chlamydia trachomatis in HPV-positive cervical cancer and cervical intraepithelial neoplasia lesions is associated with aberrations in key intracellular pathways. Intervirology 51 (2008) 230-234
17. Quint K.D., van Doorn L.J., Kleter B., de Koning M.N., van den Munckhof H.A., Morre S.A., et al. A highly sensitive, multiplex broad-spectrum PCR-DNA-enzyme immunoassay and reverse hybridization assay for rapid detection and identification of Chlamydia trachomatis serovars. J. Mol. Diagn. 9 (2007) 631-638
18. Wright T.C., Ferenczy A., and Kurman R.J. Carcinoma and other tumors of the cervix. In: Kurman R.J. (Ed). Blaustein's Pathology of the Female Genital Tract. 5th ed (1994), Springer-Verlag, New York 279-326
19. Zereu M., Zettler C.G., Cambruzzi E., and Zelmanowicz A. Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarcinoma of the uterine cervix. Gynecol. Oncol. 105 (2007) 172-175
20. Xu J.Y., Hashi A., Kondo T., Yuminamochi T., Nara M., Hashi K., et al. Absence of human papillomavirus infection in minimal deviation adenocarcinoma and lobular endocervical glandular hyperplasia. Int. J. Gynecol. Pathol. 24 (2005) 296-302
21. Kawauchi S., Kusuda T., Liu X.P., Suehiro Y., Kaku T., Mikami Y., et al. Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immunohistochemical study. Am. J. Surg. Pathol. 32 (2008) 1807-1815
22. Zielinski G.D., Snijders P.J., Rozendaal L., Daalmeijer N.F., Risse E.K., Voorhorst F.J., et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J. Pathol. 201 (2003) 535-543
23. Bulk S., Berkhof J., Bulkmans N.W., Zielinski G.D., Rozendaal L., van Kemenade F.J., et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br. J. Cancer 94 (2006) 171-175
24. Castellsagué X., Díaz M., de Sanjosé S., Muñoz N., Herrero R., Franceschi S., et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 98 (2006) 303-315
25. An H.J., Kim K.R., Kim I.S., Kim D.W., Park M.H., Park I.A., et al. Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod. Pathol. 18 (2005) 528-534
26. Tawfik El-Mansi M., Cuschieri K.S., Morris R.G., and Williams A.R. Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int. J. Gynecol. Cancer 16 (2006) 1025-1031
27. Riethdorf S., Riethdorf L., Milde-Langosch K., Park T.W., and Loning T. Differences in HPV 16- and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri. Virchows Arch. 437 (2000) 491-500
28. Anciaux D., Lawrence W.D., and Gregoire L. Glandular lesions of the uterine cervix: prognostic implications of human papillomavirus status. Int. J. Gynecol. Pathol. 16 (1997) 103-110
29. Duggan M.A., McGregor S.E., Benoit J.L., Inoue M., Nation J.G., and Stuart G.C. The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis. Hum. Pathol. 26 (1995) 319-325
30. Raab S.S., Grzybicki D.M., Zarbo R.J., Jensen C., Geyer S.J., Janosky J.E., et al. Frequency and outcome of cervical cancer prevention failures in the United States. Am. J. Clin. Pathol. 128 (2007) 817-824
31. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
32. Ault K.A. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol. Oncol. 107 (2007) S31-S33